Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution
Year: 2018
Type: review
Abstract: The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.
Source: Annals of Oncology
Institutions: The Francis Crick Institute, Cancer Research UK, University College London, Science for Life Laboratory, Karolinska Institutet, Danish Cancer Society, CRUK Lung Cancer Centre of Excellence, International AIDS Vaccine Initiative, University of Minnesota, Howard Hughes Medical Institute, Masonic Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
Funders: Howard Hughes Medical Institute, United States Agency for International Development, International AIDS Vaccine Initiative, Prostate Cancer Foundation, Breast Cancer Research Foundation, McKnight Foundation, Kræftens Bekæmpelse, Wellcome Trust, Francis Crick Institute, Cancer Research UK, National Institute for Health and Care Research, University College London, Rosetrees Trust, National Research Foundation, Danmarks Grundforskningsfond, Vetenskapsrådet, Danmarks Frie Forskningsfond, National Institutes of Health, Medical Research Council, National Cancer Institute, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W2783043796